Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Immunovant, Inc. (IMVT).

If you purchased or held Immunovant, Inc. securities between November 07, 2024 and April 22, 2025, you may be eligible to join this securities lawsuit and seek compensation for your losses.

About Immunovant, Inc.

Immunovant, Inc. is a biotechnology company that focuses on developing innovative therapies for autoimmune diseases. The company is publicly traded on the NASDAQ under the ticker symbol IMVT. Immunovant has been known for its research and development of monoclonal antibody treatments, aiming to address significant unmet needs in the autoimmune disease space.

In recent years, Immunovant has attracted attention for its ambitious clinical programs and partnerships. The company has positioned itself as a leader in the development of targeted therapies, with several compounds in various stages of clinical trials. However, the company’s progress has not been without challenges, including clinical setbacks and management turnover.

The Allegations

The lawsuit centers on whether Immunovant and certain executives misled investors by making overly optimistic statements about the company’s clinical progress and financial health. During the proposed class period, Immunovant allegedly failed to adequately disclose adverse clinical trial results, abrupt changes in leadership, and unexpected strategic pivots in its drug development plans.

Notably, in March and April 2025, Immunovant’s stock price collapsed by over 30% following the public disclosure of negative clinical developments and key management departures.

There are also concerns regarding significant insider stock sales by departing executives that occurred just before these negative announcements became public. These facts raise serious questions about whether investors were provided with all material information necessary to make informed decisions about their investments.

Class Period

The proposed class period for this investigation is November 07, 2024 to April 22, 2025. This timeframe covers the period during which the alleged misleading statements and omissions may have affected the price of Immunovant securities.

The significance of the class period is that investors who purchased or held Immunovant securities during these dates may have been impacted by the company’s alleged actions. If the investigation leads to a lawsuit, only those who acquired securities within this timeframe may be eligible to participate and seek compensation.

Your Rights and Next Steps

If you invested in Immunovant, Inc. during the proposed class period, you have important rights. At this stage, this is an investigation—not a filed lawsuit. Lawyers are ready to help determine whether you may have a claim and to guide you through the process.

You can take the following steps:

• Review your investment records to confirm purchases or holdings of Immunovant securities between November 07, 2024 and April 22, 2025.
• Stay informed about the investigation’s progress and any updates regarding potential legal action.
• Consider submitting your information through the below form to ensure you are included in any future communications about your rights and options.

Participating in the investigation does not obligate you to anything at this stage, but it ensures you are kept up to date and can make informed decisions if a lawsuit is filed.

You May Be Entitled to Compensation

If you purchased Immunovant, Inc. securities during the proposed class period, you may be eligible to join any potential lawsuit and seek compensation for your losses. Securities investigations are time-sensitive, and acting quickly can help protect your rights.

Lawyers are ready to help evaluate your case and answer your questions. To get started, complete the below form to join the investigation and learn more about your options.